Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5355157 | 0.91 | BRD4 (0.52) | BRD4LMNASMN1; SMN2HIF1A | |
| SCHEMBL5362224 | 0.87 | BRD4 (0.49) | BRD4LMNASMN1; SMN2HIF1A | |
| SCHEMBL5362228 | 0.87 | BRD4 (0.42) | BRD4LMNASMN1; SMN2HIF1A | |
| SCHEMBL5355211 | 0.85 | MEN1 (0.50) | BRD4LMNASMN1; SMN2HIF1AHPGD | |
| SCHEMBL5370560 | 0.81 | LMNA (0.46) | BRD4LMNASMN1; SMN2HIF1A | |
| SCHEMBL5351179 | 0.77 | ADORA1 (0.45) | BRD4LMNASMN1; SMN2HIF1AHCAR3 | |
| SCHEMBL5362996 | 0.74 | PDE2A (0.41) | BRD4LMNASMN1; SMN2HIF1A | |
| SCHEMBL5352149 | 0.73 | PDE2A (0.43) | BRD4LMNASMN1; SMN2HIF1A | |
| SCHEMBL5350634 | 0.73 | KDM4E (0.47) | BRD4LMNA | |
| SCHEMBL20878432 | 0.72 | MAP3K5 (0.52) | SMN1; SMN2HCAR3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202245-B2 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | PFIZER INC. (US) | 2007-04-10 | — | — | US | disclosed |
| EP-1613629-A1 | SUBSTITUTED 4-AMINO 1,2,4 TRIAZOLO 4,3-A QUINOXALINES | Pfizer Products Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004085439-A1 | SUBSTITUTED 4-AMINO[1,2,4]TRIAZOLO[4,3-A]QUINOXALINES | PFIZER PRODUCTS INC. (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192698-A1 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | PFIZER INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192698-A1 | Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines | CYP4B1, CYP3A4, CYP1B1 | BRD4 784/4885LMNA 3553/4885SMN1; SMN2 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.